calidibio.com (CLDI): חובות להיוון בספרים

The debt-to-book capitalization ratio for Calidi Biotherapeutics (CLDI), as reported by the GURU.Markets portal, highlights a current liquidity deficit and the depletion of reserves, with the ratio standing at 0.62. The company is cultivating an image as a leading center for onco-virotherapy, utilizing unique stem cell-based virus protection. Its financial model relies on attracting investment to conduct clinical trials for innovative drugs.

This indicator reflects the proportion of borrowed funds relative to equity based on book value. By analyzing this debt-to-equity chart, an investor assesses the issuer's level of financial leverage. The metric is sensitive to changes in the company's liabilities and net assets. For Calidi Biotherapeutics (CLDI), low leverage is critical, as the colossal R&D expenditures in oncolytic virotherapy require maximum financial stability.